Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.69 |
| ▸ | EGFR | P00533 | 2/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.62 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.59 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3462286 | 0.91 | HDAC2 (0.60) | SRCNR1H4HDAC2HDAC8HDAC6 | |
| SCHEMBL254400 | 0.90 | ROCK2 (0.62) | SRCEGFRROCK2ROCK1RPS6KA5 | |
| SCHEMBL3030331 | 0.90 | HDAC6 (0.63) | SRCEGFRHDAC3HDAC4HDAC1 | |
| SCHEMBL10169746 | 0.87 | ROCK2 (0.53) | SRCEGFRROCK2ROCK1RPS6KA5 | |
| SCHEMBL14082551 | 0.86 | ROCK2 (0.59) | SRCROCK2ROCK1RPS6KA5MAP4K4 | |
| SCHEMBL20804355 | 0.85 | HPGD (0.57) | SRCHDAC2HDAC8HDAC6ROCK2 | |
| SCHEMBL539059 | 0.85 | EPHX2 (0.84) | EGFREPHX2NR1H4HDAC3HDAC4 | |
| SCHEMBL25718877 | 0.84 | ROCK2 (0.74) | ROCK2ROCK1RPS6KA5MAP4K4PRKCG | |
| SCHEMBL254918 | 0.84 | ROCK2 (0.78) | EGFREPHX2NR1H4HDAC3HDAC4 | |
| SCHEMBL10194841 | 0.84 | MMP13 (0.61) | ROCK2MMP13NAMPTTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119347-A1 | BIARYL COMPOSITIONS IN COMBINATION WITH TAMOXIFEN AND METHODS FOR MODULATING A KINASE CASCADE | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2022-04-21 | — | — | US | disclosed |
| US-20210252008-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2021-08-19 | — | — | US | disclosed |
| US-10196357-B2 | Biaryl compositions and methods for modulating a kinase cascade | ATHENEX, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-2558085-B1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER | ATHENEX INC (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170196874-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | OAKTREE FUND ADMINISTRATION, LLC | 2017-07-13 | — | — | US | disclosed |
| US-9655903-B2 | Compositions and methods of treating cell proliferation disorders | ATHENEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9655903-B2 | Compositions and methods of treating cell proliferation disorders | ATHENEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9580387-B2 | Biaryl compositions and methods for modulating a kinase cascade | ATHENEX, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150182532-A1 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2015-07-02 | — | — | US | disclosed |
| US-20150182532-A1 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2015-07-02 | — | — | US | disclosed |
| US-20100249130-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2008127728-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008002676-A9 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS LLC (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008002676-A2 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2008-01-03 | — | — | WO | disclosed |
| US-7300931-B2 | Compositions for treating cell proliferation disorders | KINEX PHARMACEUTICALS, LLC (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300931-B2 | Compositions for treating cell proliferation disorders | KINEX PHARMACEUTICALS, LLC (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070197783-A1 | Compositions and methods of treating cell proliferation disorders | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197783-A1 | Compositions and methods of treating cell proliferation disorders | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070015752-A1 | Biaryl compositions and methods for modulating a kinase cascade | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-01-18 | — | — | US | disclosed |
| US-20070015752-A1 | Biaryl compositions and methods for modulating a kinase cascade | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119347-A1 | BIARYL COMPOSITIONS IN COMBINATION WITH TAMOXIFEN AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K2, MAP3K6, MAP3K8 | SRC 116/4885EGFR 376/4885EPHX2 1428/4885 |
| US-20070015752-A1 | Biaryl compositions and methods for modulating a kinase cascade | MAP3K3, MAP3K2, MAP3K20 | SRC 76/4885EGFR 537/4885EPHX2 1499/4885 |
| US-20170196874-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | SRC 76/4885EGFR 537/4885EPHX2 1499/4885 |
| US-10196357-B2 | Biaryl compositions and methods for modulating a kinase cascade | MAP3K2, MAP3K3, MAP3K6 | SRC 112/4885EGFR 464/4885EPHX2 1082/4885 |
| US-20210252008-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | SRC 76/4885EGFR 537/4885EPHX2 1499/4885 |
| US-20150182532-A1 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | MKI67, CCNC, CCNA1 | SRC 430/4885EGFR 135/4885EPHX2 2445/4885 |
| US-20070197783-A1 | Compositions and methods of treating cell proliferation disorders | MKI67, CCNC, CCNA1 | SRC 430/4885EGFR 135/4885EPHX2 2445/4885 |
| US-20100249130-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K2, MAP3K3, MAP3K6 | SRC 112/4885EGFR 464/4885EPHX2 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.